Fig. 7: EV protein markers for prediction of progression-free survival (PFS) in a MBC cohort. | Nature Communications

Fig. 7: EV protein markers for prediction of progression-free survival (PFS) in a MBC cohort.

From: Protein analysis of extracellular vesicles to monitor and predict therapeutic response in metastatic breast cancer

Fig. 7: EV protein markers for prediction of progression-free survival (PFS) in a MBC cohort.

Kaplan–Meier curves showing PFS of 59 MBC patients according to the EVP signature (a), CA 15-3 (b), CA 125 (c), CEA (d), HER2 (e), EGFR (f), PSMA (g), EpCAM (h), and VEGF (i) on EVs before treatment (baseline). The baseline level (high or low) was stratified according to the median value. The significance of the difference was calculated by a two-sided log-rank test. Hazard ratio (HR) and 95% CI were calculated using Cox proportional-hazard regression with a univariate model. Source data are provided as a Source Data file.

Back to article page